Back to Trades
Krempa David
Chief Business OfficerCIK 0001968254
Largest Purchase
No open-market purchases in the recent filings.
Profile
- Filings
- 6
- Buy transactions
- 0
- Sell transactions
- 5
- Companies
- 1
- Active
- 2025–2026
Krempa David, Chief Business Officer, has filed 6 SEC reports (2025–2026), all concentrated in Eton Pharmaceuticals, Inc. (ETON), totaling $4.4M in disclosed volume. Weighing $0 bought versus $3.2M sold, the history is heavily weighted toward selling. Data is sourced from official SEC Form 3, 4, and 5 filings.
Associated Companies
Trading History
6 loaded
| Aug 4 | ETON Eton Pharmaceuticals, Inc. | Krempa David | Chief Business Officer | Award | $0 |
| Jul 13 | ETON Eton Pharmaceuticals, Inc. | Krempa David | Chief Business Officer | Exercise | $0 |
| Jun 30 | ETON Eton Pharmaceuticals, Inc. | Krempa David | Chief Business Officer | Award | $0 |
| May 27 | ETON Eton Pharmaceuticals, Inc. | Krempa David | Chief Business Officer | Sell | $3.2M |
| Jan 14 | ETON Eton Pharmaceuticals, Inc. | Krempa David | Chief Business Officer | Award | $659.3K |
| Dec 12 | ETON Eton Pharmaceuticals, Inc. | Krempa David | Chief Business Officer | Award | $106.5K |
6 filings